HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.

Abstract
Niemann-Pick type C disease (NP-C) is a lysosomal storage disorder characterized by a progressive neurological deterioration. Different clinical forms have been defined based on patient age at neurological symptoms onset: perinatal, early infantile (EI), late infantile (LI), juvenile and adult. There is no curative treatment for NP-C. Miglustat is the first effective therapy for the neurological manifestations of NP-C patients, as it can slow down the progression of the disease. Our aim is to establish recommendations on the initiation and discontinuations with miglustat therapy based on the modified disability scale scores and describe therapeutic options to prevent treatment-related adverse effects. Four patients with different clinical forms of NP-C are reported. The modified disability scale was applied at baseline and treatment on follow up. Treatment with miglustat was initiated in patient 1 (EI form) at onset of delayed speech. Patient 2 (LI form) who started miglustat therapy in the advanced stage of the disease, died 2 years thereafter. Patient 3 (juvenile form) started treatment with miglustat at diagnosis and remains stable at four years on follow up. Patient 4, asymptomatic, is not currently treated. Miglustat has demonstrated efficacy to slow down the neurological impairment in NP-C patients assessed by the modified disability scale. Miglustat should be initiated at the onset of the first neurological symptoms. Disability scores above 20 reflect an advanced neurological impairment of the disease and miglustat therapy should be discontinued or not initiated. The gastrointestinal adverse effects can be prevented by dose titration and dietary modifications.
AuthorsMaría Socorro Pérez-Poyato, M Mar O'Callaghan Gordo, Mercé Pineda Marfa
JournalGene (Gene) Vol. 506 Issue 1 Pg. 207-10 (Sep 10 2012) ISSN: 1879-0038 [Electronic] Netherlands
PMID22750297 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
Chemical References
  • Carrier Proteins
  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • Membrane Glycoproteins
  • NPC1 protein, human
  • Niemann-Pick C1 Protein
  • 1-Deoxynojirimycin
  • miglustat
  • Glucosyltransferases
  • ceramide glucosyltransferase
Topics
  • 1-Deoxynojirimycin (administration & dosage, adverse effects, analogs & derivatives)
  • Adolescent
  • Carrier Proteins (genetics)
  • Child
  • Child, Preschool
  • Developmental Disabilities (drug therapy, physiopathology, psychology)
  • Disability Evaluation
  • Disease Progression
  • Enzyme Inhibitors (administration & dosage, adverse effects)
  • Female
  • Glucosyltransferases (antagonists & inhibitors)
  • Humans
  • Infant
  • Infant, Newborn
  • Intracellular Signaling Peptides and Proteins
  • Language Development Disorders (drug therapy, psychology)
  • Male
  • Membrane Glycoproteins (genetics)
  • Mutation
  • Niemann-Pick C1 Protein
  • Niemann-Pick Disease, Type C (drug therapy, genetics, physiopathology, psychology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: